I think one of the most important statements in the conference call was this one:
“Not necessarily. I think it's kind of business as usual there. But I think we all know that in any acquisition that there's going to be some efficiencies that you try and capture in it, some people that are changing. And so if you look at the 2 large players in the market right now, both of them are undergoing or will be undergoing sort of meaningful changes in the way that those organizations are structured. And as the aesthetics market is very much of a high-touch business, certainly, on the margin, it gives us an opportunity as a single product to really focus well and serve the customer needs.”
My wife is a dermatologist and from discussions with her and her partners the RVNC drug reps can make or break the business model. I have asked her why they always stick with Allergan’s botox and the answer is always the same. They love the Allergan drug reps because they are very easy to deal with. As an example, their dealings with the Dysport reps have always been awful and therefore they don’t use it.
I’m encouraged to see that Foley understands that it is a very “high touch business” when dealing with Dermatologists or Plastic Surgeons, etc.
Market Data 
Markets 
AI
